These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 2118823)

  • 1. Disruption of the NF-H gene increases axonal microtubule content and velocity of neurofilament transport: relief of axonopathy resulting from the toxin beta,beta'-iminodipropionitrile.
    Zhu Q; Lindenbaum M; Levavasseur F; Jacomy H; Julien JP
    J Cell Biol; 1998 Oct; 143(1):183-93. PubMed ID: 9763430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomics and mass isotopomer analysis as a strategy for pathway discovery: pyrrolyl and cyclopentenyl derivatives of the pro-drug of abuse, levulinate.
    Harris SR; Zhang GF; Sadhukhan S; Wang H; Shi C; Puchowicz MA; Anderson VE; Salomon RG; Tochtrop GP; Brunengraber H
    Chem Res Toxicol; 2013 Feb; 26(2):213-20. PubMed ID: 23171137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axonopathy-inducing 1,2-diacetylbenzene forms adducts with motor and cytoskeletal proteins required for axonal transport.
    Sabri MI; Hashemi SB; Lasarev MR; Spencer PS
    Neurochem Res; 2007 Dec; 32(12):2152-9. PubMed ID: 17577667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of exposure to 2,5-hexanediol in light or darkness on the retina of albino and pigmented rats. II. Electrophysiology.
    Nylén P; Bäckström B; Hagman M; Johnson AC; Collins VP; Höglund G
    Arch Toxicol; 1993; 67(6):435-41. PubMed ID: 8215914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing modifications of the neuronal cytoskeleton.
    Doering LC
    Mol Neurobiol; 1993; 7(3-4):265-91. PubMed ID: 8179841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoskeletal changes induced by 2,5-hexanedione on developing human neurons in vitro.
    Moretto G; Monaco S; Passarin MG; Benedetti MD; Rizzuto N
    Arch Toxicol; 1991; 65(5):409-13. PubMed ID: 1929857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of experimental giant neurofilamentous axonopathies: a unified hypothesis based on chemical modification of neurofilaments.
    Sayre LM; Autilio-Gambetti L; Gambetti P
    Brain Res; 1985 Sep; 357(1):69-83. PubMed ID: 2412663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relevance of axonal swellings and atrophy to gamma-diketone neurotoxicity: a forum position paper.
    LoPachin RM; Lehning EJ
    Neurotoxicology; 1997; 18(1):7-22. PubMed ID: 9215980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axonal transport of neurofilament is accelerated in peripheral nerve during 2,5-hexanedione intoxication.
    Monaco S; Jacob J; Jenich H; Patton A; Autilio-Gambetti L; Gambetti P
    Brain Res; 1989 Jul; 491(2):328-34. PubMed ID: 2475210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent crosslinking of neurofilaments in the pathogenesis of n-hexane neuropathy.
    Graham DG; Anthony DC; Szakál-Quin G; Gottfried MR; Boekelheide K
    Neurotoxicology; 1985; 6(4):55-63. PubMed ID: 3937075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that pyrrole formation is a pathogenetic step in gamma-diketone neuropathy.
    Genter MB; Szakál-Quin G; Anderson CW; Anthony DC; Graham DG
    Toxicol Appl Pharmacol; 1987 Feb; 87(2):351-62. PubMed ID: 3103260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbon disulfide axonopathy. Another experimental model characterized by acceleration of neurofilament transport and distinct changes of axonal size.
    Pappolla M; Penton R; Weiss HS; Miller CH; Sahenk Z; Autilio-Gambetti L; Gambetti P
    Brain Res; 1987 Oct; 424(2):272-80. PubMed ID: 2445451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of gamma-diketone neurotoxicity: non-neurotoxicity of 3,3-dimethyl-2,5-hexanedione, a gamma-diketone incapable of pyrrole formation.
    Sayre LM; Shearson CM; Wongmongkolrit T; Medori R; Gambetti P
    Toxicol Appl Pharmacol; 1986 Jun; 84(1):36-44. PubMed ID: 3715867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giant axonopathy characterized by intermediate location of axonal enlargements and acceleration of neurofilament transport.
    Monaco S; Wongmongkolrit T; Shearson CM; Patton A; Schaetzle B; Autilio-Gambetti L; Gambetti P; Sayre LM
    Brain Res; 1990 Jun; 519(1-2):73-81. PubMed ID: 2118823
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.